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Relative fat mass at baseline and its 
early change may be a predictor 
of incident nonalcoholic fatty liver 
disease
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The relationship between changes in body components and the risk of nonalcoholic fatty liver disease 
(NAFLD) is not fully understood. We investigated the effects of body components and subsequent 
changes on incident NAFLD at follow-up ultrasound scanning in a longitudinal cohort. We included 
9967 participants without NAFLD at baseline who underwent serial health examinations. Sex-
specific, weight-adjusted skeletal muscle index  (SMI_Wt) was used. Mean follow-up duration was 
48.5 ± 33.5 months. NAFLD developed in 2395 participants (24.0%). Body composition was measured 
using bioelectrical impedance analysis. The following baseline body components were significantly 
associated with incident NAFLD: the lowest and middle  SMI_Wt tertiles in the normal-weight group 
(adjusted hazard ratio [aHR] = 2.20 and 1.54, respectively), and fat percentage in the normal-weight 
(aHR = 1.12), overweight (aHR = 1.05), and obese groups (aHR = 1.03) (all P < 0.05). Among 5,033 
participants who underwent ≥ 3 health examinations,  SMI_Wt increase between the first and second 
examinations was an independent protective factor against incident NAFLD in non-obese groups 
(P < 0.05). Increased fat percentage was an independent risk factor for incident NAFLD in all weight 
categories (P < 0.05). High fat mass at baseline may be a better predictor of incident NAFLD than 
muscle mass. Reciprocal changes in fat and muscle mass during the first year of follow-up predicted 
incident NAFLD in non-obese groups.
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Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver diseases, repre-
senting approximately 25% of global  prevalence1. NAFLD is a spectrum of liver diseases related to metabolic 
abnormalities, ranging from simple hepatic steatosis to nonalcoholic steatohepatitis with varying degrees of 
fibrosis, or even  cirrhosis2. Patients with NAFLD have increased risks of hepatic or non-hepatic malignancies, 
cardiovascular events, and increased  mortality3.
Although obesity is a risk factor for  NAFLD4, the relationship between body composition and NAFLD appears 
complex. Incident NAFLD development is associated with insulin resistance and weight  gain5. However, body 
mass index (BMI) is an imperfect measurement of adiposity and metabolic abnormality that does not distin-
guish between fat and muscle. Cut-off values of BMI to determine obesity differ for ethnic  groups6. Moreover, 
body composition cannot be readily predicted by BMI, given that similar BMI may represent variable degrees 
of visceral adiposity, which is known to predispose the development of  NAFLD7.
Recent studies have shown that overweight and obesity in metabolically healthy individuals are associated 
with a greater risk of incident NAFLD than that in normal weight  individuals8. Higher muscle mass showed an 
inverse correlation with incident NAFLD, and increase in muscle mass suggested beneficial effects in NAFLD 
 development9. Notwithstanding, the complex relationship between weight change (or body composition) with 
time and NAFLD development has not been fully explored. In this study, we investigated the effects of baseline 
values and changes in body composition on the development of incident NAFLD in a longitudinal cohort.
Results
Baseline characteristics. Overall, 9967 participants were included in the study (Fig. 1). The baseline char-
acteristics of the study participants are summarized in Table 1. The mean age was 45.9 ± 10.8 years, and 6156 
(61.8%) participants were men. The mean BMI was 22.3 ± 2.8 kg/m2. Study participants were categorized accord-
ing to their BMI as underweight (n = 710, 7.1%), normal weight (n = 5457, 54.8%), overweight (n = 2182, 21.9%), 
and obese (n = 1618, 16.2%).
During follow-up (mean follow-up duration, 48.5 ± 33.5 months), incident NAFLD was observed in 2395 
participants (24.0%; incident rate 59.4 per 1000 person-years). Participants with incident NAFLD were more 
frequently older (47.1 vs 45.6 years), were men (55.2% vs 32.9%), had higher baseline BMI (23.7 vs 21.8), and 
were more likely to have metabolic abnormalities (53.1% vs 33.6%) than those without NAFLD (all P < 0.001). 
In the study groups, incident NAFLD developed in 6.6%, 17.6%, 30.3%, and 45.0% of the underweight, normal 
weight, overweight, and obese groups, respectively (P < 0.001) (Table 1). Calculation of serum fibrosis indices in 
participants with incident NAFLD demonstrated that an absolute majority was classified as low risk for all indices 
including NAFLD fibrosis score (< − 1.455: n = 2393, 99.9%), fibrosis score-4 (FIB-4, < 1.3: n = 1852, 77.3%), and 
aspartate aminotransferase-to-platelet ratio index (APRI, < 0.5: n = 2108, 88.8%).
Relationships between baseline body composition parameters and incident NAFLD during 
follow-up among BMI subgroups. Given that baseline muscle and fat masses were significantly different 
among the subgroups according to BMI cut-off values (underweight, normal weight, overweight, and obese; 
Figure 1.  Flowchart for patient selection.
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Supplementary Table S1), associations among baseline body composition parameters and incident NAFLD were 
investigated in each BMI subgroup using multivariate Cox regression analysis (Table 2).
Table 1.  Baseline characteristics of the study subjects. Frequencies and percentages for categorical variables, 
mean ± standard deviations for continuous variables. NAFLD nonalcoholic fatty liver disease, BMI body 
mass index, SMI_Wt weight-adjusted skeletal muscle index, AST aspartate aminotransferase, ALT alanine 
aminotransferase, GGT γ-glutamyl transpeptidase, LDL low-density lipoprotein, HDL high-density 
lipoprotein, WBC white blood cell, eGFR estimated glomerular filtration rate, HSI hepatic steatosis index, TyG 
triglyceride-glucose index, SBP systolic blood pressure, DBP diastolic blood pressure, T1 lowest tertile, T2 
middle tertile, T3 highest tertile.
All (n = 9967) Incident NAFLD (n = 2395) No incident NAFLD (n = 7572) P
Age (years) 45.9 ± 10.8 47.1 ± 10.1 45.6 ± 11.0  < 0.001
Sex, male (%) 3811 (38.2) 1321 (55.2) 2490 (32.9)  < 0.001
BMI (kg/m2) 22.3 ± 2.8 23.7 ± 2.7 21.8 ± 2.7  < 0.001
BMI < 18.5 710 (7.1) 47 (2.0) 663 (8.8)
18.5 ≤ BMI < 23 5457 (54.8) 958 (40.0) 4499 (59.4)
23 ≤ BMI < 25 2182 (21.9) 662 (27.6) 1520 (20.1)
BMI ≥ 25 1618 (16.2) 728 (30.4) 890 (11.8)
Waist–hip ratio 0.83 ± 0.08 0.87 ± 0.07 0.82 ± 0.08  < 0.001
Soft lean mass (kg) 42.0 ± 8.0 45.1 ± 8.4 41.0 ± 7.6  < 0.001
SMI_Wt 69.7 ± 5.4 68.7 ± 5.5 70.0 ± 5.4  < 0.001
Sex-specific SMI_Wt tertiles (%)
T1 3323 (33.3) 1183 (49.4) 2140 (28.3)  < 0.001
T2 3326 (33.4) 771 (32.2) 2555 (33.7)
T3 3318 (33.3) 441 (18.4) 2877 (38.0)
Fat mass (kg) 14.9 ± 4.4 16.7 ± 4.5 14.3 ± 4.2  < 0.001
Fat percentage (%) 24.6 ± 5.5 25.5 ± 5.5 24.3 ± 5.5  < 0.001
AST (IU/L) 20 (17–24) 20 (17–25) 19 (17–23)  < 0.001
ALT (IU/L) 16 (12–22) 19 (15–27) 15 (12–21)  < 0.001
GGT (IU/L) 17 (12–26) 21 (15–34) 15 (12–23)  < 0.001
Total cholesterol (mg/dL) 190.3 ± 34.3 194.1 ± 34.5 189.1 ± 34.1  < 0.001
Triglycerides (mg/dL) 86 (65–121) 109 (78–154) 81 (62–110)  < 0.001
LDL cholesterol (mg/dL) 119.3 ± 31.2 124.5 ± 31.6 117.7 ± 31.0  < 0.001
HDL cholesterol (mg/dL) 56.6 ± 13.1 52.1 ± 12.2 58.0 ± 13.0  < 0.001
Glucose (mg/dL) 91 (86–97) 94 (87–100) 91 (85–97)  < 0.001
Uric acid (mg/dL) 4.8 ± 1.3 5.2 ± 1.3 4.6 ± 1.2  < 0.001
WBC  (103/µL) 5.52 (4.66–6.57) 5.97 (5.04–7.11) 5.40 (4.56–6.41)  < 0.001
Hemoglobin (g/dL) 14.0 ± 1.6 14.5 ± 1.6 13.9 ± 1.5  < 0.001
Platelets  (103/µL) 260.7 ± 58.6 267.3 ± 57.7 258.5 ± 58.7  < 0.001
Creatinine (mg/dL) 0.8 (0.68–0.94) 0.9 (0.7–1.0) 0.8 (0.7–0.9)  < 0.001
eGFR (ml/min/1.73  m2) 89.6 ± 22.4 87.1 ± 21.4 90.4 ± 22.7  < 0.001
HSI 33.7 ± 3.4 34.0 ± 3.2 33.5 ± 3.5  < 0.001
TyG 8.3 ± 0.5 8.6 ± 0.5 8.3 ± 0.5  < 0.001
Hypertension, N (%) 1480 (14.8) 493 (20.6) 987 (13.0)  < 0.001
Diabetes, N (%) 263 (2.6) 107 (4.5) 156 (2.1)  < 0.001
SBP (mmHg) 118.8 ± 14.7 122.6 ± 14.5 117.6 ± 14.6  < 0.001
DBP (mmHg) 73.4 ± 9.9 76.1 ± 9.6 72.6 ± 9.8  < 0.001
Alcohol (≥ 1 time/week), N (%) 3,475 (50.9) 804 (55.1) 2,671 (49.7)  < 0.001
Current smoking, N (%) 904 (13.3) 298 (20.5) 606 (11.3)  < 0.001
Exercise (≥ 1 times/week), N (%) 4,056 (60.6) 896 (62.3) 3,160 (60.1) 0.137
No. of components of metabolic syndrome, N (%)
0 6,150 (61.7) 1,124 (46.9) 5,026 (66.4)  < 0.001
1 2,696 (27.0) 785 (32.8) 1,911 (25.2)
2 899 (9.0) 377 (15.7) 522 (6.9)
 ≥ 3 222 (2.2) 109 (4.6) 113 (1.4)
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In the normal weight subgroup, participants in the lowest sex-specific, weight-adjusted skeletal muscle index 
 (SMI_Wt) tertile (T1) were significantly associated with an increased adjusted hazard ratio (aHR = 2.20; 95% 
confidence interval [CI], 1.77–2.73.; P < 0.001) for incident NAFLD after adjusting for age, sex, blood pressure, 
glucose, triglyceride, high-density lipoprotein (HDL), uric acid, and smoking status (Model 2, Table 2). Partici-
pants in T2 (the middle  SMI_Wt) were also significantly associated with an increased adjusted hazard ratio for 
NAFLD (aHR = 1.54; 95% CI 1.33–1.79; P < 0.001) (Model 2, Table 2).
In the other BMI subgroups (underweight, overweight, and obese), low muscle mass was not significantly 
associated with NAFLD development. On the contrary, fat percentage (FP) was significantly associated with 
incident NAFLD in the normal weight (aHR = 1.12; 95% CI 1.09–1.15; P < 0.001), overweight (aHR = 1.05; 95% 
CI 1.02–1.09; P < 0.001), and obese (aHR = 1.03; 95% CI 1.00–1.05; P = 0.04) subgroups.
Figure 2 depicts the cumulative incidences of NAFLD according to  SMI_Wt and FP tertiles. Participants in 
the lowest tertile of  SMI_Wt (T1) showed the highest risk for incident NAFLD, followed by those in the middle 
and highest tertiles (Fig. 2a; P < 0.001 by log-rank test). Accordingly, participants in the highest tertile of FP had 
the highest risk for incident NAFLD, followed by those in the middle and lowest tertiles (Fig. 2b; P < 0.001 by 
log-rank test).
Among noninvasive fibrosis indices, NAFLD fibrosis score had a weak negative correlation with the baseline 
muscle mass and FIB-4 had a weak positive correlation with the baseline fat mass (Supplementary Table S2).
Development of incident NAFLD and its relationship with changes in clinical parameters 
between first and second examinations. Of the entire study population, 5033 participants under-
went a health examination three or more times during the study period, with a median interval of 1.2 years 
(interquartile range 1.0–2.0) between the first and second examinations. Changes in body composition and 
clinical parameters between the first and second examinations are summarized in Table 3. Participants in the 
underweight and normal-weight groups showed increases in body weight and FP, with a decrease in  SMI_Wt, 
whereas participants in the overweight and obese groups showed decreases in body weight, with no change or 
increase in  SMI_Wt and no change or decrease in FP, respectively (all P < 0.001). In addition, significantly posi-
tive correlations were observed between increased weight, between the first and second examinations (ΔWt), 
and harmful changes in metabolic parameters (increased systolic and diastolic blood pressures, triglyceride, 
and glucose levels, and decreased HDL cholesterol; all P < 0.001) (Table 4). We further investigated the associa-
tion between changes in these parameters and incident NAFLD development in the 5033 participants (Table 5). 
Increase in  SMI_Wt between the first and second examinations was an independent protective factor against 
incident NAFLD in the underweight (aHR = 0.76; 95% CI 1.61–0.95; P = 0.015), normal-weight (aHR = 0.93; 
95% CI 0.89–0.97; P = 0.002), and overweight groups (aHR = 0.90; 95% CI 1.84–0.96; P = 0.002) after adjustment 
for multiple covariates and baseline values. Moreover, FP increase was an independent risk factor for incident 
NAFLD in all weight categories (all P < 0.05).
Figure 3 depicts the cumulative incidences of NAFLD according to the tertiles of changes in  SMI_Wt and FP. 
Participants in the highest tertile of FP change showed the highest risk for incident NAFLD, followed by those 
in the middle and lowest tertiles (Fig. 3b; P = 0.01 by log-rank test). However, differences among the subgroups 
according to change in  SMI_Wt tertiles were nonsignificant (Fig. 3a; P = 0.1 by log-rank test).
Assessment of the changes in body composition measurements showed no significant correlation with fibrosis 
indices (Supplementary Table S3).
Post hoc analysis: metabolic dysfunction-associated fatty liver disease as the alternative out-
come. According to the recently proposed diagnostic  criteria10, 1914 subjects were identified as metabolic 
dysfunction-associated fatty liver disease (MAFLD) out of 2395 subjects with NAFLD (79.9%). Unlike the over-
weight and obese groups, the number of subjects was decreased 63.8% in the lean group (MAFLD, n = 17, vs 
NAFLD, n = 47) and 43.7% in the normal-weight group (MAFLD, n = 539, vs. NAFLD, n = 958). Associations 
between MAFLD development and low muscle mass/high FP at baseline were consistent with those on the 
Table 2.  Baseline risk factors for incident NAFLD according to BMI categories. Model 1: adjusted for age, sex 
and smoking; Model 2: Model 1 and further adjusted for blood pressure, glucose, triglyceride, HDL and uric 
acid. BMI body mass index, aHR adjusted hazard ratio, CI confidence interval, SMI_Wt weight-adjusted skeletal 
muscle index, HDL high- density lipoprotein.
BMI < 18.5 18.5 ≤ BMI < 23.0 23.0 ≤ BMI < 25.0 BMI ≥ 25.0
aHR 95% CI P aHR 95% CI P aHR 95% CI P aHR 95% CI P
Model 1
Lowest  SMI_Wt tertile NA 2.90 2.35–3.57  < 0.001 1.35 0.98–1.87 0.070 1.66 0.95–2.88 0.073
Middle  SMI_Wt tertile 1.77 0.39–8.00 0.456 1.80 1.55–2.09  < 0.001 1.09 0.79–1.51 0.604 1.46 0.82–2.61 0.198
Fat percentage 1.07 0.96–1.18 0.223 1.16 1.13–1.18  < 0.001 1.07 1.03–1.11  < 0.001 1.05 1.02–1.07  < 0.001
Model 2
Lowest  SMI_Wt tertile NA 2.20 1.77–2.73  < 0.001 1.22 0.88–1.70 0.235 1.46 0.84–2.54 0.185
Middle  SMI_Wt tertile 2.11 0.45–9.99 0.345 1.54 1.33–1.79  < 0.001 1.01 0.73–1.40 0.972 1.40 0.78–2.50 0.260
Fat percentage 1.07 0.96–1.19 0.201 1.12 1.09–1.15  < 0.001 1.05 1.02–1.09 0.001 1.03 1.00–1.05 0.038
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development of NAFLD (aHR for MAFLD = 3.05 [95% CI 2.29–4.07] vs aHR for NAFLD = 2.20 [95% CI 1.77–
2.73]) (Supplementary Table S4). However, in contrast to NAFLD, change in muscle mass was not significantly 
associated with the development of MAFLD in the low bodyweight group, and the effect was smaller in the nor-
mal- weight group (aHR for MAFLD = 0.86 [95% CI 0.81–0.91] vs aHR for NAFLD = 0.93 [95% CI 0.89–0.97]) 
(Supplementary Table S5).
Figure 2.  Kaplan–Meier curves for NAFLD-free survival according to weight-adjusted relative muscle and 
fat mass at baseline. (a) NAFLD-free survival according to sex-specific muscle mass tertiles. (b) NAFLD-free 
survival according to fat percentage tertiles. NAFLD nonalcoholic fatty liver disease, T1 lowest tertile, T2 middle 
tertile, T3 highest tertile.
Table 3.  Changes in clinical parameters between baseline and follow-up examinations in subjects who 
underwent three or more health examinations (n = 5,033). BMI body mass index, SMI_Wt weight-adjusted 
skeletal muscle index, FP fat percentage, SBP systolic blood pressure, DBP diastolic blood pressure, HDL high-
density lipoprotein, TG triglyceride.
Changes in parameters BMI < 18.5 18.5 ≤ BMI < 23.0 23.0 ≤ BMI < 25.0 BMI ≥ 25.0 P
ΔWeight (kg) 0.7 ± 1.5 0.3 ± 1.7 − 0.1 ± 2.1 − 0.5 ± 2.3  < 0.001
ΔSMI_Wt − 0.9 ± 2.1 − 0.4 ± 2.1 0.0 ± 2.2 0.3 ± 2.3  < 0.001
ΔFP (%) 0.8 ± 1.9 0.4 ± 1.8 0.0 ± 1.9 − 0.3 ± 2.0  < 0.001
ΔSBP (mmHg) − 0.2 ± 8.1 − 0.2 ± 10.0 − 1.6 ± 10.7 − 1.6 ± 10.9  < 0.001
ΔDBP (mmHg) − 0.1 ± 6.2 − 0.5 ± 6.5 − 1.0 ± 6.6 − 1.2 ± 6.7 0.012
ΔHDL (mg/dL) 0.2 ± 7.1 − 0.1 ± 6.5 0.0 ± 6.3 0.4 ± 5.9 0.230
ΔTG (mg/dL) 1.7 ± 26.5 3.4 ± 32.1 0.0 ± 39.6 − 2.5 ± 50.4  < 0.001
ΔGlucose (mg/dL) 1.3 ± 6.7 0.5 ± 7.9 0.9 ± 6.7 1.1 ± 10.7 0.081
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Discussion
This population-based longitudinal study suggested that high baseline fat mass rather than muscle mass may 
be a better predictor for incident NAFLD across BMI categories in participants without NAFLD at baseline. 
Moreover, reciprocal changes in fat and muscle masses during the first year of follow-up also predicted incident 
NAFLD in the non-obese population. Both findings were significantly associated with NAFLD development 
after adjustment for metabolic parameters.
The incidence rate of NAFLD in the present study (59.4 per 1000 person-years) was comparable to the pooled 
incidence rates in Asia (50.9 per 1000 person-years) in a recent systematic  review11. The incremental incidence 
rates in subgroups with higher BMI categories reaffirmed the role of obesity in the development of  NAFLD12. 
However, because BMI is an imperfect marker of adiposity or body fat  distribution13, decreased or excess com-
ponents of body composition at a given time and their changes with time were investigated to understand their 
roles in NAFLD development in various BMI categories. Low skeletal muscle mass has been suggested as a risk 
factor for NAFLD, considering the important role of skeletal muscles in insulin-mediated glucose disposal and 
secretion of  myokines14,15.
Several recent studies have reported the relevance of sarcopenia as a risk factor for NAFLD, mostly in cross-
sectional settings. According to a study based on a Korean nationwide survey, sarcopenia was independently 
associated with an increased prevalence of NAFLD defined by hepatic steatosis index score after adjusting for 
obesity or insulin  resistance16. Other studies have also reported an association between low muscle mass and 
NAFLD prevalence in cross-sectional  settings17,18. Recently, a longitudinal retrospective cohort study from Korea 
demonstrated that relative skeletal muscle mass at baseline was inversely associated with NAFLD development 
and positively associated with the resolution of  NAFLD9. Because NAFLD incidence differed significantly among 
different BMI subgroups in the present study, we explored risk factors for incident NAFLD among the four dif-
ferent BMI subgroups. Consistent with former studies, the results of the present study for 9967 participants with 
at least two health examinations suggested associations between reduced relative muscle mass at baseline and 
incident NAFLD risk in the normal-weight group in a dose-dependent manner, after adjustment for multiple 
confounders.
Additionally, our results indicated that high baseline fat mass was a better predictor for incident NAFLD 
than low muscle mass in the normal-weight, overweight, and obese groups. From the Rotterdam study of a large 
population-based cohort, cross-sectional analysis showed that both high fat mass and low muscle mass were 
associated with NAFLD in normal-weight women (BMI < 25), whereas fat mass was a better predictor for NAFLD 
prevalence in both  sexes19. Likewise, our results suggested that relative excess of fat mass predicted incident 
NAFLD better in all study populations except in participants with BMI < 18.5, whereas low muscle mass was only 
significant in the normal-weight subgroup. In addition, changes between the first and second health examinations 
were investigated to identify their relationship with the development of NAFLD in participants who underwent 
three or more health checkups during the study period (n = 5033). Even in the case of relatively small changes 
in body weight, muscle mass, and fat mass between the first and second examinations, differences among the 
Table 4.  Correlation between changes in metabolic parameters and changes in weight or body composition 
variables in subjects who underwent three or more health examinations. SMI_Wt weight-adjusted skeletal 
muscle index, SBP systolic blood pressure, DBP diastolic blood pressure, HDL high-density lipoprotein, TG 
triglyceride, FP fat percentage, Wt body weight.
(a) Correlation with weight change ΔSMI_Wt ΔSBP ΔDBP ΔHDL ΔTG ΔGlucose ΔFP
Correlation with ΔWeight (kg) − 0.62 0.13 0.07 − 0.09 0.16 0.06 0.62
P for partial correlation  < 0.001  < 0.001  < 0.001  < 0.001  < 0.001  < 0.001  < 0.001
(b) Correlation with changes in muscle mass ΔWt ΔSBP ΔDBP ΔHDL ΔTG ΔGlucose ΔFP
Correlation with ΔSMI_Wt − 0.62 − 0.07 − 0.07 − 0.02 − 0.08 − 0.06 − 0.94
P for partial correlation  < 0.001  < 0.001  < 0.001 0.265  < 0.001  < 0.001  < 0.001
Table 5.  Changes in body composition parameters and risk of incident NAFLD according to BMI categories. 
Model 1: adjusted for age, sex and baseline values; Model 2: Model 1 and further adjusted for changes in 
blood pressure, glucose, triglyceride, HDL and uric acid. BMI body mass index, aHR adjusted hazard ratio, CI 
confidence interval, SMI_Wt weight-adjusted skeletal muscle index, HDL high- density lipoprotein.
BMI < 18.5 18.5 ≤ BMI < 23.0 23.0 ≤ BMI < 25.0 BMI ≥ 25.0
aHR 95% CI P aHR 95% CI P aHR 95% CI P aHR 95% CI P
Model 1
ΔSMI_Wt 0.78 0.64–0.96 0.016 0.93 0.89–0.98 0.002 0.91 0.86–0.97 0.006 0.95 0.89–1.01 0.071
ΔFat percentage 1.48 1.19–1.86 0.001 1.10 1.05–1.16  < 0.001 1.16 1.07–1.25  < 0.001 1.10 1.03–1.18 0.005
Model 2
ΔSMI_Wt 0.76 0.61–0.95 0.015 0.93 0.89–0.97 0.002 0.90 0.84–0.96 0.002 0.95 0.89–1.01 0.094
ΔFat percentage 1.44 1.14–1.83 0.002 1.11 1.05–1.17  < 0.001 1.18 1.09–1.28  < 0.001 1.11 1.03–1.19 0.006
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four BMI subgroups were significant concerning the direction of changes (Table 3). Table 4 shows that changes 
in weight were correlated with changes in body composition and metabolic abnormalities, that is, even a small 
amount of weight gain was associated with blood pressure elevation, serum glucose and triglyceride increases, 
and HDL cholesterol decrease in addition to reduced muscle mass and increased fat mass. These findings sug-
gest an evolving process toward metabolic abnormalities in NAFLD development as in previous studies, which 
reported insulin resistance or low adiponectin in non-obese participants with  NAFLD20,21.
Considering the small, but significant, reciprocal changes in muscle and fat mass accompanying weight 
changes in our study participants, we further explored the relationship between changes in body composition 
parameters and incident NAFLD risk. A significant increase in incident NAFLD risk was noted per percent 
increase in fat mass after adjustment for baseline values and other confounders in all BMI categories between 
the first and second examinations with a median interval of 1.2 years (Table 5). However, the degree of increase 
in incident NAFLD risk per percent decrease in muscle mass showed less robustness overall, as well as a non-
significant association in the obese group. A recent single-center retrospective study from Korea reported that 
a progressive increase in fat mass and loss of muscle mass with aging was significantly associated with incident 
NAFLD, particularly in non-obese participants, between baseline and follow-up health examinations at 10 years22. 
However, loss of muscle mass over a longer time period is an aging  process23. Instead of evaluating the effect 
of aging on NAFLD development, we focused on the effect of early changes in body composition from the 
perspective of NAFLD prevention. Studies have demonstrated the efficacy of lifestyle intervention in prevent-
ing progression to diabetes in individuals with prediabetes, even compared with  metformin24,25. Similarly, our 
results show that if participants with unfavorable body composition at baseline achieve an increase in muscle 
mass and more importantly decrease in fat mass over a 1- or 2-year period, even small amounts of such changes 
can reduce the risk of future NAFLD.
Generally, Asians have proportionately higher body fat for a given BMI than people of other  races26,27. Non-
obese Asian participants with NAFLD have a higher body fat content compared with those with comparable BMI 
without  NAFLD28. Therefore, more robustness of fat mass compared with muscle mass in terms of NAFLD risk in 
the present study must be validated in other populations, including those in the West. Although there have been 
Figure 3.  NAFLD-free survival duration according to changes in weight-adjusted relative muscle and fat mass 
during follow-up. (a) NAFLD-free survival according to tertiles of changes in sex-specific muscle mass. (b) 
NAFLD-free survival according to tertiles of changes in fat percentage. NAFLD nonalcoholic fatty liver disease, 
T1 lowest tertile, T2 middle tertile, T3 highest tertile.
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several Western studies on the relationship between body composition and NAFLD, which included advanced 
nonalcoholic  steatohepatitis29,30, similar studies in a presumably healthy population are scarce, except for the 
Rotterdam  study19. Despite its cross-sectional design, the results of the Rotterdam study at least underscore the 
relative importance of fat mass in NAFLD risk. Additionally, a recent randomized controlled trial from Hong 
Kong concluded that NAFLD remission was achieved with lesser weight reduction through lifestyle interven-
tions in non-obese patients compared with obese  patients31. The effect of fat mass and its changes on NAFLD 
development, particularly in the non-obese participants of the present study, suggest common pathophysiologic 
processes to those in the Hong Kong study in which non-obese patients achieved NAFLD remission with a mod-
est degree of weight  reduction31.
Recently, an international expert consensus statement recommended an updated definition of MAFLD instead 
of  NAFLD32. MAFLD may more accurately reflects current knowledge of fatty liver diseases associated with 
metabolic dysfunction than NAFLD. When we applied MAFLD as the outcome, the change in muscle mass was 
not significantly associated with the development of MAFLD in the low bodyweight group and the effect was 
smaller in the normal-weight group. These results may have been affected by the smaller number of subjects in 
the lean group and normal-weight groups. However, the associations between MAFLD development and low 
muscle mass/high FP at baseline were consistent with the NAFLD results.
The present study had several limitations. First, NAFLD diagnosis was based on ultrasonography, instead 
of liver biopsy, which is the gold standard for the diagnosis of and severity assessment for NAFLD. Addition-
ally, the use of ultrasonography for diagnosis raises concerns about possible misclassification bias of incident 
NAFLD diagnosis, which may weaken the associations found. However, recommending or performing liver 
biopsy in presumably healthy individuals could raise an ethical concern, considering that this study exclusively 
enrolled health checkup examinees. Second, the bioelectrical impedance analyzer used in this study was unable 
to determine the distribution (android or gynoid) of the fat mass, which is known to be related to metabolic 
abnormalities and  NAFLD19,33. In addition, assessment of visceral adiposity, such as abdominal fat computed 
tomography, was unavailable. Third, the database lacked information on muscle function, such as grip strength, 
which is one of the various aspects in the assessment of  sarcopenia34. Fourth, noninvasive techniques for NAFLD 
severity assessment, such as transient elastography, was not included in the health examination programs. Fifth, 
the present study included health checkup examinees from Korea, which may limit generalization of the results 
to other settings or ethnic groups with different cut-off values of BMI for obesity and different body composi-
tion  patterns27,35. Lastly, we were unable to assess the effect of genetic variants due to the study design (lack of 
study samples). Recent genetic studies suggest a possible link between altered body composition and the devel-
opment of NAFLD, for example, higher prevalence of patatin-like phospholipase domain-containing protein 
3 (PNPLA3) [G] allele among non-obese individuals, an association between transmembrane 6 superfamily 
member 2 (TM6SF2) rs58542926 genotype and NAFLD that was independent of obesity, and interferon lambda 
4 variant in non-obese nonalcoholic  steatohepatitis20,36,37. More detailed studies are required to confirm the 
mechanistic link among genetic factors, body composition, and the risk of NAFLD.
In summary, although low muscle mass at baseline was a significant predictor for incident NAFLD in indi-
viduals with normal weight, high baseline fat mass predicted incident NAFLD in overweight and obese partici-
pants, as well as in those with normal weight, in this large-scale population-based study. In addition, reciprocal 
changes in fat and muscle masses during the first year of follow-up predicted incident NAFLD in participants 
with BMI < 25 kg/m2. The results of the present study add to the rationale of lifestyle interventions to prevent 
NAFLD development in individuals with high relative fat mass regardless of body habitus. Prospective valida-
tion is warranted for a bidirectional relationship between NAFLD and fat mass, that is, the effect of changes in 
body composition on incident NAFLD development, as well as resolution/progression of preexisting NAFLD 
with lifestyle intervention.
Methods
Study subjects and follow-up. In this study, 19,717 consecutive adult participants who had undergone 
a comprehensive health examination with two or more follow-up examinations between January 2007 and 
December 2018 at the Health Promotion Center of Gangnam Severance Hospital (Seoul, Korea) were included; 
some of the participants were offered health-screening examinations by their employers and the others vol-
untarily participated in health evaluation follow-up programs. The information obtained in the questionnaire 
included frequency of drinking alcohol per week and average amounts of alcohol consumed at a time. Alcohol 
intake was calculated based on drinking frequency and the amount of alcohol per drink for alcoholic beverages. 
The exclusion criteria were (1) fatty liver by baseline ultrasound (n = 5953), (2) alcohol intake > 30 g/day for men 
and > 20 g/day for women (n = 1,724), (3) positive serology for hepatitis B surface antigen and/or hepatitis C anti-
body (n = 796), (4) suspicious chronic liver disease (n = 130) or malignancy (n = 58) on baseline imaging stud-
ies, and (5) missing data on anthropometric measurements, body composition analysis findings, or ultrasound 
results (n = 1089). Finally, 9967 participants were included in the study (Fig. 1). Informed consent was obtained 
from all participants and only de-identified data were used from the routine health screening. The study protocol 
was approved by the Institutional Review Board of Gangnam Severance Hospital (IRB No. 3-2016-0280). The 
study protocol conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki.
Diagnosis of NAFLD. Abdominal ultrasonography was performed by seven experienced radiologists who 
were blinded to the clinical and laboratory characteristics of the study participants at the time of the exami-
nation. The diagnosis of fatty liver was based on the presence of at least two ultrasonographic features: (1) a 
diffuse increase in the fine echoes of the liver parenchyma compared with the spleen or kidney parenchyma; 
(2) ultrasound beam attenuation; and (3) poorly visualized intrahepatic  structures38. Serum fibrosis markers 
9
Vol.:(0123456789)
Scientific Reports |        (2020) 10:17491  | https://doi.org/10.1038/s41598-020-74659-9
www.nature.com/scientificreports/
were calculated for participants with incident NAFLD using laboratory values at the time of NAFLD diagnosis, 
including NAFLD fibrosis score, fibrosis score-4 (FIB-4), and aspartate aminotransferase-to-platelet ratio index 
(APRI)39–41.
The diagnosis of MAFLD was based on the evidence of hepatic steatosis (i.e., ultrasonographic fatty liver), in 
addition to one of the following three criteria: overweight/obesity (BMI ≥ 23 kg/m2), presence of type 2 diabetes 
mellitus, or evidence of metabolic  dysregulation10.
Clinical and laboratory assessments. A standardized, self-administered questionnaire was used to col-
lect information on demographic characteristics, smoking status, preexisting medical conditions, and medica-
tion use. Height was measured to the nearest 0.1 cm using a stadiometer. Weight was measured to the nearest 
0.1 kg and BMI was calculated as weight in kilograms divided by height in meters squared. The participants 
were categorized according to BMI based on the Korean Society for the Study of Obesity practice guidelines: 
underweight (BMI < 18.5), normal weight (18.5 ≤ BMI < 23), overweight (23 ≤ BMI < 25), and obese (BMI > 25)42. 
Blood samples were obtained following overnight fasting for 10–12 h. The laboratory tests included complete 
blood count, liver biochemistry, total cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, glu-
cose, hepatitis B surface antigen, and antibody to hepatitis C virus. Hypertension was defined as a systolic blood 
pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or current use of  antihypertensives43. Diabetes was 
defined as a fasting serum glucose ≥ 126 mg/dL or self-reported insulin or antidiabetic  use44.
Measurement of body composition parameters. Body composition was measured using bioelectrical 
impedance analysis through tissue conductivity (X-SCAN Plus, Jawon Medical Co., Seoul, Korea)45, according 
to the manufacturer’s instructions. Briefly, study participants avoided eating or drinking 8 h before measure-
ment and drinking alcohol 24 h before measurement. They grasped the handles of the device and contacted 
the electrodes while standing for up to 5 min. Skeletal muscle index was defined as total skeletal muscle mass/
weight × 100, a modified formula according to the study of Janssen and  colleagues34,46–48.
We divided participants using sex-specific, weight-adjusted SMI tertiles  (SMI_Wt; T1, T2, and T3). The relative 
proportion of body fat mass component was expressed as a percentage of total body  weight49. Change in body 
composition between the first and second health examinations was calculated by subtracting baseline  SMI_Wt or 
fat percentage (FP) from their corresponding values at the second health examination.
Statistical analysis. Baseline characteristics are expressed as frequencies and percentages for categorical 
variables, and as mean ± standard deviations for continuous variables. Student’s t-test, χ2 test, and analysis of 
variance were used to compare variables. Variables with skewed distribution were converted to natural loga-
rithms for further analysis. The Kaplan–Meier method was used to describe the cumulative incidence of NAFLD 
at follow-up ultrasound scanning, and the log-rank test was used for comparison. Covariate variables were 
selected through a stepwise method of Cox proportional hazards analysis, excluding duplicate indicators among 
the significant variables related to NAFLD in univariate analysis, and were considered in multivariate analysis. 
Multivariate-adjusted Cox proportional hazards analysis was used to determine the hazard ratio of NAFLD at 
follow-up according to relevant variables. All tests were based on two-sided probability, and P < 0.05 was consid-
ered statistically significant. All analyses were performed using the SAS 9.4 (SAS Institute, Cary, NC, USA) and 
R 3.3.2 software packages (R Foundation for Statistical Computing, Vienna, Austria). R software (“survival” and 
“rms” packages) was used for the Kaplan–Meier analysis and survival plot.
Data availability
The data analyzed during the current study are available from the corresponding author on reasonable request.
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